Article
Cancer Risks for PMS2-Associated Lynch Syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Oct 2018
Ten Broeke Sanne W, van der Klift Heleen M, Tops Carli M J, Aretz Stefan, Bernstein Inge, Buchanan Daniel D, de la Chapelle Albert, Capella Gabriel, Clendenning Mark, Engel Christoph, Gallinger Steven, Gomez Garcia Encarna, Figueiredo Jane C, Haile Robert, Hampel Heather L, Hopper John L, Hoogerbrugge Nicoline, von Knebel Doeberitz Magnus, Le Marchand Loic, Letteboer Tom G W, Jenkins Mark A, Lindblom Annika, Lindor Noralane M, Mensenkamp Arjen R, Møller Pål, Newcomb Polly A, van Os Theo A M, Pearlman Rachel, Pineda Marta, Rahner Nils, Redeker Egbert J W, Olderode-Berends Maran J W, Rosty Christophe, Schackert Hans K, Scott Rodney, Senter Leigha, Spruijt Liesbeth, Steinke-Lange Verena, Suerink Manon, Thibodeau Stephen, Vos Yvonne J, Wagner Anja, Winship Ingrid, Hes Frederik J, Vasen Hans F A, Wijnen Juul T, Nielsen Maartje, Win Aung Ko
Abstract excerpt
PURPOSE: Lynch syndrome due to pathogenic variants in the DNA mismatch repair genes MLH1, MSH2, and MSH6 is predominantly associated with colorectal and endometrial cancer, although extracolonic cancers have been described within the Lynch tumor spectrum. However, the age-specific cumulative risk (penetrance) of these cancers is still poorly defined for PMS2-associated Lynch syndrome. Using a large data set from...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.